Israel HealthCare Ventures

Israel HealthCare Ventures (IHCV) is a leading Israeli life sciences venture capital fund founded in 2000 and based in Tel Aviv. The firm has raised two funds, IHCV I and IHCV II, cumulatively investing approximately $135 million across 27 companies in Israel-based startups. Founder and Managing Partner Hadar Ron leads the firm with a hands-on investment approach, preferring to hold board seats in portfolio companies and providing professional advice, ongoing management support, and access to a global network of medical and financial contacts. IHCV invests from seed to later stages across medical devices, biotechnology, pharmaceuticals, life sciences, nanotechnology, and medical-related IT. Approximately 75% of the portfolio consists of medical device companies, with the remaining 25% in pharmaceuticals and biotechnology. Investment checks are typically in the $3 million to $10 million range, and the firm leads rounds. The portfolio spans medical fields including cardiology, orthopedics, oncology, general surgery, gastroenterology, esthetics, and central nervous system disorders, covering therapeutic and diagnostic technologies as well as rehabilitation, drug delivery, and consumer healthcare. Co-investors include Teva Pharmaceuticals. The portfolio has achieved 3 IPOs and 3 acquisitions. The most significant exit is Mazor Robotics, a surgical robotics company acquired by Medtronic for $1.7 billion in September 2018. Gamida Cell, a cell therapy company, completed its NASDAQ IPO in October 2018, raising $139 million in total. Xylo Technologies also achieved an IPO exit. Other notable companies in the portfolio include CorAssist, OrSense, and Optonol. IHCV's two-decade track record in Israeli life sciences reflects the firm's consistent focus on technology that addresses large patient populations with unmet clinical needs. The firm's extensive global medical network enables portfolio companies to access regulatory expertise, clinical partnerships, and commercial relationships across the United States, Europe, and Asia.